Inserm teams led by Prof. Jean-Yves Blay and Christophe Caux in Lyon , and by Franck Tirode and Olivier Delattre in Paris have just demonstrated a new genetic variant in tumours that had not been identified until now
researchers from Maria-Elena Torres-Padilla’s team have pushed the limits of science even further. They managed to obtain totipotent cells with the same characteristics as those of the earliest embryonic stages and with even more interesting properties.
A team at the Institut de Génétique et de Biologie Moléculaire et Cellulaire has evidenced, at the atomic scale, the threedimensional structure of the complete human ribosome and the detailed interactions that occur within it.
Research efforts associating scientists from the CNRS, UVSQ and INSERM within the Laboratoire END-ICAP, working in collaboration with a team from the University of Bern, has demonstrated the therapeutic potential of a new class of synthetic oligonucleotides in the treatment of Duchenne muscular dystrophy using RNA "surgery".
Bisphenol F and bisphenol S, which are used as substitutes for bisphenol A in certain applications, have the same negative effect on human foetal testes as bisphenol A. This has recently been shown by René Habert and his colleagues at the Joint Research Unit 967 "Stem Cells, Radiation and Genetic Instability"
A team from the Institut de biologie at the Ecole normale supérieure (CNRS/ENS/INSERM)(2) has described how in Paramecia, mating types are transmitted from generation to generation through an unexpected mechanism.
Des régions non codantes du génome semblent diminuer la sévérité de deux maladies des globules rouges : la bêta thalassémie et la drépanocytose
A team of researchers directed by Frédéric Coin, Inserm Research Director at the Institute of Genetics and Molecular and Cellular Biology (IGBMC) in Strasbourg (a Joint Inserm/CNRS/University of Strasbourg Research Unit), has discovered a new drug that inhibits repair: spironolactone, which seems likely to be used in the very short term as an adjuvant to chemotherapy.
A team of French researchers, led by Dr. Anna Buj-Bello (Genethon/Inserm) and teams at the University of Washington and Harvard Medical School in the United States, have demonstrated the efficacy of gene therapy in models of myotubular myopathy, an extremely severe neuromuscular disease in children.
A French and English team (AP-HP, Inserm, UPEC, CEA/Mircen, Oxford Biomedica, Cambridge University) has conducted a clinical phase 1/2 gene therapy study among patients suffering from an evolved form of Parkinson’s disease. Fifteen patients were able to benefit from this new treatment, which involves injecting a vector expressing the genes of three enzymes that are essential for the biosynthesis of dopamine, which is lacking in Parkinson’s disease. Thanks to...